Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest
safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple
myeloma.